Until the costs of Protons can justify the purported improvements for the vast majority of hpv- 4a typical chemo xrt patients... IMRT will remain the standard and we can continue to explore reducing ENI to its verifiable safe minimum.. Or one can just assume immunotherapy will be the eventual savior. Pro? Ton$!
Thanks for reading. Clearly costs enter in somewhere. That said, there is nuance and conflation with large institution pricing that muddies the water. Most NCCN institutions receive more per fx of IMRT than we get for protons. And just last week, good contact with "prestigious" institution receiving 4x our per fx rate within their adaptive IMRT program. So as you know, payments and US financial implications are quite complicated. I have quite a few articles on here related to pricing / business etc. if interested.
Until the costs of Protons can justify the purported improvements for the vast majority of hpv- 4a typical chemo xrt patients... IMRT will remain the standard and we can continue to explore reducing ENI to its verifiable safe minimum.. Or one can just assume immunotherapy will be the eventual savior. Pro? Ton$!
Thanks for reading. Clearly costs enter in somewhere. That said, there is nuance and conflation with large institution pricing that muddies the water. Most NCCN institutions receive more per fx of IMRT than we get for protons. And just last week, good contact with "prestigious" institution receiving 4x our per fx rate within their adaptive IMRT program. So as you know, payments and US financial implications are quite complicated. I have quite a few articles on here related to pricing / business etc. if interested.